V-set and immunoglobulin domain containing 1 (VSIG1) as an emerging target for epithelial–mesenchymal transition of gastric cancer

Catalin-Bogdan Satala¹, Ioan Jung¹, Zsolt Kovacs², Raluca-Ioana Stefan-Van Staden³, Calin Molnar⁴, Tivadar Bara⁴, Andrei-Ionut Patrichi¹,⁵ & Simona Gurzu¹,⁵*

V-set and Immunoglobulin domain containing 1 (VSIG1) is a cell–cell adhesion molecule whose role in the genesis and evolution of gastric cancer (GC) is not understood. Only three Medline-indexed papers have focused on the role of VSIG1 in GC. The clinicopathological features of 94 GCs were examined in association with immunohistochemical (IHC) patterns of VSIG1, E-cadherin, and β-catenin which were assessed in the tumor core (central) vs. invasive edge. Cases were classified depending on the VSIG1 expression: membrane/membrane in both core and invasive front; null/negative staining in both core and invasive front; and cases with translational patterns: membrane core/cytoplasmic buds and cytoplasmic core/null buds. Most of the tumors showed null pattern (n = 54). Cases with translational patterns (n = 20) were GCs with a high lymph node ratio value (≥0.26) and advanced Dukes-MAC-like stage. Of the 20 total cases, 9 showed membrane-to-nuclear translocation of β-catenin and loss of E-cadherin, as indicators of epithelial–mesenchymal transition. All cases with membrane/membrane pattern (n = 20) involved the distal stomach. The poorest overall survival was registered in patients with subcellular translocation of VSIG1, compared to those with either membrane/membrane or null patterns (p = 0.002). In GC, VSIG1 acts as an adhesion membrane protein but its membrane-cytoplasmic translocation can be an indicator of epithelial–mesenchymal transition due to cytoplasmic VSIG1-mediated activation of canonical Wnt/β-catenin signaling pathway.

Despite major improvements in diagnostic and therapeutic tools in oncology, gastric cancer (GC) remains one of the top causes of cancer-related deaths worldwide. More than one million new cases were diagnosed in 2020, and almost 770,000 patients with GC died in that year¹. GC resistance to chemotherapy is partially explained by its being one of the most heterogeneous tumors from the phenotypic, genetic and molecular points of view²,³. The first classification of GC was established by Lauren more than 50 years ago and is still in use⁴. In recent decades, many molecular classification systems, such as those suggested by The Cancer Genome Atlas (TCGA) and the Asian Cancer Research Group (ACRG) have been proposed⁵,⁶. Several biomarkers with possible prognostic or predictive impact in GC have also been identified in the last decade. One of these biomarkers is V-set and Immunoglobulin domain containing 1 (VSIG1), a cell surface protein in the junction adhesion molecule (JAM) family that is encoded by VSIG1 gene located on chromosome Xq22.3⁷. Also known as glycoprotein A34 (GpA34), VSIG1 was firstly characterised by Scanlan et al.⁸. Although it was initially considered a gastric-restricted biomarker, its presence was further demonstrated in other normal and neoplastic tissues, such as ovary, testis, lung and liver⁹–¹¹.

¹Department of Pathology, George Emil Palade University of Medicine, Pharmacy, Science and Technology, Targu Mures, Romania. ²Department of Biochemistry, George Emil Palade University of Medicine, Pharmacy, Science and Technology, Targu Mures, Romania. ³National Institute of Research for Electrochemistry and Condensed Matter, Bucharest, Romania. ⁴Department of Surgery, George Emil Palade University of Medicine, Pharmacy, Science and Technology, Targu Mures, Romania. ⁵Research Center for Oncopathology and Translational Medicine (CCOMT), George Emil Palade University of Medicine, Pharmacy, Science and Technology, Targu Mures, Romania. *email: simonagurzu@yahoo.com
In gastric mucosa, VSIG1 was shown to be indispensable for normal glandular differentiation, but the relevance of its subcellular localization (membrane vs. cytoplasm) in gastric tumor cells is unknown. To the best of our knowledge, between 2006 and 2021, only three studies were focused on the role of VSIG1 in GC. The authors of these studies concluded that VSIG1 is a cell adhesion molecule which loss of expression in tumor cells is associated with a worse prognosis. The mechanism of its loss has not yet been described.

The purpose of this study was to examine the potential prognostic role of VSIG1 in GC patients, based on its pattern of expression in the tumor core and the invasive edge, which is also known as the tumor invasion front. Whether VSIG1 expression was associated with epithelial–mesenchymal transition (EMT) was also assessed.

Materials and methods

Selection of cases. This is an observational study that enrolled 94 randomly selected patients with GC diagnosed between 2017 and 2021 in the Department of Pathology, Clinical Emergency Hospital of Targu Mures, Romania. The present study was approved by the Ethics Committee Board of the Clinical Emergency Hospital of Targu Mures, Romania and was exempted from informed consent for those included retrospectively. All methods were performed in accordance with the relevant guidelines and regulations of our institution.

The inclusion criteria were surgically treated GC cases (subtotal or complete gastrectomy, with D2/D3 lymphadenectomy), with at least 3 months postoperative survival and without adjuvant therapy prior to intervention. Patients with tumors other than intestinal and diffuse type carcinoma (e.g. hepatoid carcinoma, choriocarcinoma, plasmacytoid carcinoma), inoperable or recurrent carcinomas, or metastatic tumors of the stomach were excluded.

Tissue microarray blocks. For all cases, the histological slides were reviewed, and tumor buds were counted for adenocarcinomas. Then, after microscopic analysis of all tumor sections stained with haematoxylin and eosin (HE), the most representative slide from each case, with at least 80% viable tumor cells and without necrosis or haemorrhage was chosen. For tissue microarray (TMA) blocks, two representative areas were marked for each case: one from the tumor core and one from periphery (invasion front). These two areas of interest were removed from the formalin-fixed paraffin-embedded tissue blocks (donor blocks), using a TMA instrument (Histopathology Ltd., Hungary) that enabled the cutting of sections of 4 mm in diameter.

Histopathological analysis. All cases were assessed based on Lauren’s classification and restaged according to the 5th edition of the World Health Organization (WHO) manual for Digestive System Tumors. In addition to TNM (tumor, node, metastasis) stage, the cases were also classified based on the Dukes-MAC-like staging system proposed in 2017 by Gurzu et al. Budding index at the tumor front of invasion was assessed with regard to TNM stage, as a prognostic factor. The median follow-up was 31 months (range 3–59 months) after surgery.

Immunohistochemical assessment. Immunohistochemical (IHC) examinations were done using antibodies for VSIG1 (rabbit polyclonal HPA036311; Sigma-Aldrich; dilution 1:200), E-cadherin (clone NCH-38; Dako Agilent Technologies, Inc.; dilution 1:50), and β-catenin (clone β-catenin-1; Dako Agilent; dilution 1:150). The TMA sections (5 μm thickness) were deparaffinized and rehydrated, followed by endogenous peroxidase blocking (incubation for 5 min at room temperature with EnVision™ FLEX Peroxidase Blocking solution). Antigen retrieval was performed at high temperature for 30–40 min, with high pH retrieval solution. This was followed by a 20-min incubation at room temperature with Dako EnVision™ FLEX/HRP detection reagent. EnVision™ FLEX diaminobenzidine (DAB) was used to develop the stains and counterstaining of nuclei was done with Mayer’s hematoxylin.

Since all cases were assessed on TMA blocks, a cut-off value of 15% was used for all the three IHC antibodies, to consider a case as positive. Hepatic tissue served as an external positive control for membrane E-cadherin and β-catenin and for cytoplasmic VSIG1. Normal gastric mucosa was used as a control tissue for membrane VSIG1.

The classification of the cases took into account the subcellular pattern of VSIG1 in tumor cells, in the core vs. the invasion front. Based on the subcellular patterns (core vs. front) we grouped the cases into three categories: type I—membrane positivity in both the tumor core and at the front of invasion; homologous pattern type II—null reaction in both core and front (negative cases); and heterologous pattern type III—membrane positivity in the tumor core, with cytoplasmic translocation at the tumor front and type B—cytoplasmic positivity in the tumor core, with loss of VSIG1 (negative) at the front of invasion (Fig. 1).

E-cadherin and β-catenin membrane expression were considered markers of an epithelial phenotype, while cases with membrane-to-nuclear translocation of β-catenin and loss of E-cadherin expression at the tumor front (buds) were considered tumors with EMT, as in our previous studies.

Statistical analysis. The included cases were statistically assessed using GraphPad Prism software (version 8, software-free version). To determine the association between clinicopathological features and IHC markers, multivariate analysis methods (the Pearson χ²), as well as chi-square and Fisher's exact tests were used, with p values less than 0.05 being considered statistically significant. Cox proportional hazard regressions were applied to estimate the individual hazard ratio (HR) for overall survival (OS), OS rates being estimated using the same software and Kaplan–Meier curves. The median follow-up was 31 months (range 3–59 months) after surgery.
Institutional review board statement. The Approval of Ethical Committee of Clinical Emergency Hospital of Targu Mures, Romania was obtained for performing the present study.

Informed consent. Informed consent was taken from every patient included in the prospective database. Part of the study was retrospective.

Results

Clinicopathological parameters. Most of the patients included in this study were over 60 years (range 39–86, with a mean age of 65.5 years). The male to female ratio was 3.47:1. It was a statistically significant predominance of location on the distal stomach (p = 0.013). Half of the tumors were differentiated adenocarcinomas with lymph node metastases (pN1–3) at the time of diagnosis (Table 1). 75% of tumors were assessed as type I (intestinal phenotype) according to Lauren’s classification; the other 25% were type II (diffuse/poorly-cohesive) carcinomas (Table 2). The mean LNR was 0.28 ± 0.08. Lymphovascular and perineural invasions were present in 78.9% and 61.7% of cases, respectively (Table 2).

Regarding the invasive edge, high-grade budding adenocarcinomas (b3) were mostly de-differentiated (25 G3 and 1 G2). All diffuse carcinomas (n = 23) were also considered as b3. A high budding index at the invasion front was associated with lymphovascular (p = 0.0009) and perineural invasion (p = 0.003) but it was not linked with the risk of distant metastases (p = 0.11). Tumors with advanced pT stage (T3–4), as well as those with advanced Dukes-MAC-like stage (C2–D), were associated with a high budding index at the invasion front. The positive association of the score of b3 confirmed it with the presence of lymph node metastases (Fig. 2).

VSIG1 subcellular localization. From all the examined clinicopathological factors, the VSIG1 expression pattern showed a statistically significant correlation with regional lymph node status, LNR, and Dukes-MAC-like stage (Table 2). Of the 94 included cases, only 28 were diagnosed in the proximal part of the stomach: 10 belonged to the heterologous types A and B (r = 1.00) and 18 to the homologous type II group (r = 0.38). Tumor localization was found to slightly influence VSIG1 reactivity (p = 0.04) which was associated with the EMT phenomenon described below in the text (Figs. 3 and 4).

Homologous type I pattern was displayed by 20 GCs, mainly occurring in tumors diagnosed in males over 60 years, independent of the histologic subtype or grade of differentiation. This immunophenotype was associated
with an early Dukes-MAC-like stage and a lower LNR compared with the other groups. Only one of the 17 cases with distant metastases belonged to this group. VSIG1 membrane positivity in core and invasive edge mostly associated with E-cadherin and β-catenin membrane positivity, as indicators of epithelial phenotype (Table 2 and Fig. 3).

### Table 1. Clinicopathological features of the 94 gastric cancer cases. Significant values are in bold.

| Parameter                                      | Number/% (n = 94) | p value |
|------------------------------------------------|------------------|---------|
| Median age (standard deviation)                | 69 years (±9.14) | –       |
| Gender                                         |                  |         |
| Male                                           | 73/77.6%         | 0.013   |
| Female                                         | 21/22.4%         |         |
| Tumor location                                 |                  |         |
| Proximal                                       | 28/29.79%        | 0.038   |
| Distal                                         | 66/70.21%        |         |
| Histologic type and grade of differentiation (G)|          |         |
| G1/2 adenocarcinoma                            | 46/48.9%         |         |
| G3 adenocarcinoma                              | 25/26.6%         | 0.063   |
| Poorly cohesive (diffuse) carcinoma            | 23/24.5%         |         |
| Depth of invasion (pT stage)                   |                  |         |
| pT1                                            | 10/10.6%         | 0.009   |
| pT2                                            | 6/6.4%           |         |
| pT3                                            | 23/24.5%         |         |
| pT4a                                           | 42/44.7%         |         |
| pT4b                                           | 13/13.8          |         |
| Regional lymph node status (pN stage)          |                  |         |
| pN0                                            | 26/27.6          | 0.033   |
| pN1–3                                          | 68/72.4%         |         |
| Distant metastases (pM stage)                  |                  |         |
| M0                                             | 77/81.9%         | 0.008   |
| M1                                             | 17/18.1%         |         |
| Dukes-MAC-like stage                           |                  |         |
| A1 (pT1N0)                                     | 9/9.6%           |         |
| A2 (pT1N1–3)                                   | 1/1.1%           |         |
| B1 (pT2N0)                                     | 6/6.4%           |         |
| B2 (pT2N1–3)                                   | –                | 0.056   |
| C1 (pT3N0)                                     | 5/5.3%           |         |
| C2 (pT3N1–3)                                   | 18/19.2%         |         |
| D (pT4N0–3)                                    | 55/58.4%         |         |

Table 1. Clinicopathological features of the 94 gastric cancer cases. Significant values are in bold.

Homologous type II pattern was displayed by 54 GCs. These were mostly epithelial adenocarcinomas, similar to the homologous type I cases (Fig. 3), but showed a higher tendency for lymph node (high LNR) and distant metastases, compared with the first group, especially for cases with over 5 buds at the invasion front (Table 2).

Heterologous pattern was found to be significantly associated with factors of aggressiveness, including advanced stage, high LNR, and risk of distant metastases. Type B was predominant (n = 15); only 5 cases belonged to type A group. Although not statistically significant, this immunophenotype was rather characteristic for poorly cohesive and de-differentiated (G3) adenocarcinomas with over 10 buds at the invasion front (Table 2).

Presence of the EMT in the invasive edge, with total or partial loss of E-cadherin and membrane-nuclear translocation of β-catenin (Fig. 4) reflected a mesenchymal phenotype which was not expressed by the other two patterns (Fig. 3).

### Survival rate.

Kaplan–Meier curves showed that the OS was correlated with presence of lymph node metastases (p = 0.002) and an advanced (C2–D) Dukes-MAC-like stage (p = 0.003). No correlations with tumor location (p = 0.12), pT stage (p = 0.07) or budding index was found (p = 0.49). A shorter OS for patients with heterologous pattern of VSIG1 expression (A and B) was seen, when compared to those with homologous type I and II. The Cox proportional hazard model was used as a regression model to investigate the prognostic value of VSIG1 expression patterns, as follows: VSIG1 homologous type I pattern does not significantly influence the survival, compared to homologous type II pattern (hazard ratio (HR) = 0.96, p = 0.126). On the other hand, both A and B heterologous patterns showed an almost complete overlapping in terms of OS curves, with a HR of 1.09, p = 0.04 and HR of 1.07, p = 0.03 (Fig. 5).
Table 2. VSIG1 pattern of expression is statistically significant correlated to regional lymph node status, lymph node ratio and Dukes-MAC-like stage, but not to tumor depth of invasion. At the same time, β-catenin and E-cadherin statuses are significantly different between the three VSIG1 patterns. Significant values are in bold.

|                        | VSIG1 homologous type I (n = 20) | VSIG1 homologous type II (n = 54) | VSIG1 heterologous (type A and B) (n = 20) | p value |
|------------------------|----------------------------------|-----------------------------------|------------------------------------------|---------|
| **Gender**             |                                  |                                   |                                          |         |
| Male                   | 16/80%                           | 39/72.22%                         | 18/90%                                   | 0.254   |
| Female                 | 4/20%                            | 15/27.78%                         | 2/10%                                    |         |
| **Age**                |                                  |                                   |                                          |         |
| ≤ 60                   | 6/30%                            | 8/14.81%                          | 5/25%                                    | 0.294   |
| > 60                   | 14/70%                           | 46/85.19%                         | 15/75%                                   |         |
| **Lauren’s histologic subtype** |                              |                                   |                                          |         |
| Intestinal type        |                                  |                                   |                                          |         |
| G2 Adeno-carcinoma     | 11/55%                           | 27/50%                            | 8/40%                                    | 0.356   |
| G3 Adeno-carcinoma     | 4/20%                            | 17/31.48%                         | 4/20%                                    |         |
| Diffuse/poorly cohesive subtype | 5/25%                           | 10/18.52%                         | 8/40%                                    |         |
| **pT stage**           |                                  |                                   |                                          |         |
| Early pT (pT1–2)       | 5/25%                            | 9/16.66%                          | 1/5%                                     | 0.219   |
| Advanced pT (pT3–4)    | 15/75%                           | 45/83.34%                         | 19/95%                                   |         |
| **pN stage**           |                                  |                                   |                                          |         |
| N0                     | 8/40%                            | 15/27.78%                         | 1/5%                                     | 0.033   |
| N1+                    | 12/60%                           | 39/72.22%                         | 19/95%                                   |         |
| **pM stage**           |                                  |                                   |                                          |         |
| Mx                     | 19/95%                           | 42/77.78%                         | 16/80%                                   | 0.224   |
| M1                     | 1/5%                             | 12/22.22%                         | 4/20%                                    |         |
| **Resection margins**  |                                  |                                   |                                          |         |
| R0                     | 17/85%                           | 44/81.48%                         | 14/70%                                   | 0.444   |
| R1                     | 3/15%                            | 10/18.52%                         | 6/30%                                    |         |
| **Lymphovascular invasion** |                                |                                   |                                          |         |
| LV0                    | 6/30%                            | 12/22.22%                         | 2/10%                                    | 0.292   |
| LV1                    | 14/70%                           | 42/77.78%                         | 18/90%                                   |         |
| **Perineural invasion**|                                  |                                   |                                          |         |
| n0                     | 10/50%                           | 21/38.88%                         | 5/25%                                    | 0.264   |
| n1                     | 10/50%                           | 33/61.12%                         | 15/75%                                   |         |
| **Tumor budding in front of invasion** |                         |                                   |                                          |         |
| b1                     | 5/25%                            | 10/18.52%                         | 2/10%                                    | 0.462   |
| b2                     | 4/20%                            | 19/35.18%                         | 5/25%                                    |         |
| b3                     | 11/55%                           | 25/46.3%                          | 13/65%                                   |         |
| **Dukes-MAC-like stage** |                                  |                                   |                                          |         |
| Early (A–B–C1)         | 8/40%                            | 10/18.52%                         | 1/5%                                     | 0.020   |
| Advanced (C2–D)        | 12/60%                           | 44/81.48%                         | 19/95%                                   |         |
| **Lymph node ratio**   |                                  |                                   |                                          |         |
| 0.00                   | 9/45%                            | 15/27.78%                         | 1/5%                                     | 0.0022  |
| 0.01–0.25              | 6/30%                            | 16/29.62%                         | 2/10%                                    |         |
| ≥ 0.26                 | 5/25%                            | 23/42.6%                          | 17/85%                                   |         |
| **EMT markers**        |                                  |                                   |                                          |         |
| β-catenin expression   |                                  |                                   |                                          |         |
| Membrane               | 19/95%                           | 48/88.9%                          | 11/55%                                   | 0.0007  |
| Nucleus                | 1/5%                             | 6/11.1%                           | 9/45%                                    |         |
| E-cadherin expression  |                                  |                                   |                                          |         |
| Membrane               | 18/90%                           | 47/87%                            | 11/55%                                   | 0.004   |
| Negative               | 2/10%                            | 7/13%                             | 9/45%                                    |         |
Discussion

VSIG1 is a relatively newly discovered protein whose role is, to date, incompletely understood. It is a member of the Immunoglobulin superfamily. Like other members of this family, it possesses an extracellular, immunoglobulin-like domain, with a role in intercellular adhesion, and a C-terminal cytoplasmic domain, bounded by a transmembrane region. This subcellular distribution could explain the membrane-to-cytoplasm translocation of VSIG1 revealed in this study in GC.

In normal human tissues, VSIG1 was initially found to be expressed only in normal gastric mucosa and then in testis. In the 12 published studies in total, from which three were focused on the GC, it was highlighted that other normal tissues and few epithelial tumors can also display VSIG1 positivity. Loss of membrane expression was seen to associate a worse evolution.

Cytoplasmic granular/dot-like VSIG1 immunostaining was firstly proved by our team, during a Romanian-Japan interdisciplinary research project, in normal hepatocytes and a histologic subtype of hepatocellular...
canceroma (HCC) which was called by the researchers as “gastric-type HCC”. As this is the first report about the membrane to cytoplasmic translocation of VSIG1 in GC, it is difficult to find a reliable explanation for the unusual translocation.

Because the gastric-type HCC and hepatoid-type of GC seems to share a common origin, in the endodermal rest of the foregut, as we have already hypothesized, it is worth considering whether the presence of VSIG1 cytoplasmic immunostaining in HCC cells is a sign of gastric differentiation, or the reverse, that cytoplasmic pattern of VSIG1 expression in GC cells is a sign of hepatoid differentiation. Nevertheless, cytoplasmic immunostaining should be interpreted as an indicator of retro-differentiation towards a common “hepato-gastric” embryologic lineage (Fig. 6). This mechanism might explain why the heterologous GCs were associated with the parameters of aggressiveness and had a poor OS compared to those with homologous patterns.

This theory can help understanding occurrence of the cytoplasmic stain in some heterologous cases. It is still difficult to understand why some VSIG1-negative cases (homologous type II) showed a similar behaviour with the cases with diffuse membrane immunoreactivity (homologous type I).

On the one hand, the embryologic endodermal development can be, at least mechanistically, divided into two different processes: (i) the pre-patterning of endoderm into foregut, midgut, and hindgut, followed by (ii) the regionalization of those three embryologic structures by the end of gastrulation. The pre-patterning process was proven to be regulated by several transcription factors. VSIG1, on the other hand, act as a regulator of the (ii) regionalization process, being indispensable for the differentiation of glandular gastric epithelium. Due to these similarities between VSIG1 patterns of cytoplasmic expression in gastric- and hepatoid type carcinomas, it is, in our opinion, highly probable to exist a molecular linkage from developmental perspective between those two tumors. The same stepwise mechanisms might be involved in gastric and hepatic carcinogenesis as those above-mentioned, but in a reverse manner. So, in light of those, our theory is centered on two different, but
continuous processes of retrodifferentiation: a one-step retrodifferentiation towards stomach/hepatic primordia—deregionalization and a two-step retrodifferentiation—depatterning towards a common gastro-hepatic primordium (Fig. 6).

The histologic transition between “forestomach” and “mid-hindstomach” is overlapped by the transition between VSIG1-negative squamous epithelium, covering the initial segment of stomach primordium, and VSIG1-positive gastric-type glandular epithelium, present on the remnant gastric primordium. Although this remains to be demonstrated, the theory of regionalization-dependent tumors might explain why some of VSIG1 null GCs (homologous type II pattern) still exhibit an OS rate similar to that of homologous type I cases (membrane positivity but loss of membrane positivity in the invasion front (heterologous type A) associate aggressive behaviour.

According to this embryologic theory, homologous type II cases with good OS should be located preferentially in the proximal segment of the stomach, a hypothesis that was partially confirmed in our study. These tumors did not lose the positivity (as a sign of EMT) but they were rather developed from rests of VSIG1 negative pre-patterning endodermis. When they derive from the embryological rests of VSIG1 positive regionalized endodermis, they keep the membrane positivity (homologous type A) and associate slowly metastatic behaviour. In these cases, if the EMT is activated (heterologous VSIG1), it induces loss of cohesivity with a high-grade budding index and increased invasiveness. We were not able to find any data in the literature to support our hypothesis, but this theory deserves further attention, particularly in larger cohorts. In carcinogenesis, however, members of tight junctions family, of which the adhesion protein VSIG1 is a part, have gained much attention in recent decades.

Another interesting result of this paper was the correlation between cytoplasmic expression of VSIG1, nuclear translocation of β-catenin and loss of E-cadherin expression. Considering that E-cadherin loss and membrane-to-nuclear β-catenin translocation are indicators of EMT, it can be stipulated that VSIG1 cytoplasmic positivity (homologous type A and B) could be also considered surrogate markers for EMT. Having similar patterns of staining to β-catenin and E-cadherin, it is probable that VSIG1 plays a role in EMT by modulating Wnt pathway in a similar fashion. Yet to be demonstrated, with the confirmation of this hypothesis, VSIG1 would become an even more intriguing molecule, having two opposite roles: in embryogenesis, it might act as a glandular-epithelial differentiation marker, but in carcinogenesis, its role is diverted, becoming an EMT activator, a marker of mesenchymal phenotype. It was already demonstrated that acquisition of epithelial cell plasticity is intimately related to multiple changes in Wnt pathway. In canonical Wnt pathway, the key regulator is β-catenin, of which accumulation in the cytoplasm and then nuclear translocation, leads to the activation of specific transcription factor of TCF/LEF family. As this is, to the best of our knowledge, the first study to raise the possibility of VSIG1 involvement in tumor cell plasticity, specifically in EMT and Wnt pathway in a similar fashion to β-catenin, further research is needed to establish whether the same transcriptional patterns are used by VSIG1, or the molecular machinery is different, at least in part.

Regarding the general clinical-pathological features, our study demonstrated similar results to those published in literature: in our cohort, factors of aggressiveness were found to be a high lymph node ratio, with a propensity towards poorly differentiated adenocarcinomas or diffuse carcinomas, as well as an advanced Dukes-MAC-like stage. Also, as expected, the overall survival was negatively influenced by the presence of lymph node metastasis/ higher lymph node ratio, and distant metastases.

In conclusion, when located in the membrane of tumor cells, VSIG1 acts as an adhesion membrane protein, as it was previously highlighted. Although the mechanism of membrane-cytoplasmic translocation of VSIG1 is
not known, it is probably induced by VSIG1-mediated activation of canonical Wnt/β-catenin signaling pathway. The hypothesis needs to be validated by further experimental studies.

Limitations of the study consist in the small cohort but, as the senior author is an experienced gastrointestinal pathologist, she can certify the results. We started this VSIG1 observation in 2014 but did not publish the result due to the scarce data from literature which did not allow external validation. Other limitations is lack of statistical correlation between VSIG1 expression and molecular classification of GC. This was not done because only 6 of the 94 cases showed microsatellite instability and Epstein–Barr-induced carcinomas are quite rare in our geographic area.

Data availability

The database details are available at the corresponding authors upon request.

Received: 25 April 2022; Accepted: 6 September 2022
Published online: 28 September 2022

References

1. GLOBOCAN 2020: Stomach. https://gco.iarc.fr/today. Accessed December 22, 2022.
2. Ho, S. W. T. & Tan, P. Dissection of gastric cancer heterogeneity for precision oncology. Cancer Sci. 110, 3405–3414. https://doi.org/10.1111/cas.14191 (2019).
3. Rocken, C. Molecular classification of gastric cancer. Expert Rev. Mol. Diagn. 17, 293–301. https://doi.org/10.1080/14737519.2017.1269895 (2017).
4. Lauren, P. The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol. Microbiol. Scand. 64, 31–49. https://doi.org/10.1111/apmn.1965.64.1.31 (1965).
5. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513, 202–209. https://doi.org/10.1038/nature13480 (2014).
6. Cristescu, R. et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat. Med. 21, 449–456. https://doi.org/10.1038/nm.3850 (2015).
7. Kim, J. H. et al. Gastric-type expression signature in serrated pathway-associated colorectal tumors. J. Gastrointest. Oncol. 10, 286–293. https://doi.org/10.1016/j.jgo.2019.02.006 (2019).
8. Scanlan, M. J. et al Glycoprotein A34, a novel target for antibody-based cancer immunotherapy. Cancer Immun. 6, 2 (2006).
9. VSIG1 V-set and immunoglobulin domain containing 1 [Homo sapiens (human)]—Gene—NCBI. https://www.ncbi.nlm.nih.gov/gene/340547. Accessed December 28, 2021.
10. Inoue, Y. et al. Characterization of V-set and immunoglobulin domain containing 1 exerting a tumor suppressor function in gastric, lung, and esophageal cancer cells. Cancer Sci. 108, 1701–1714. https://doi.org/10.1111/cas.13295 (2017).
11. Jung, Y. E. et al. V-set and immunoglobulin domain-containing 1 (VSIG1), predominantly expressed in testicular germ cells, is dispensable for spermatogenesis and male fertility in mice. Animals (Basel) 11, 1037. https://doi.org/10.3390/ani11041037 (2021).
12. Oudovsambuu, O. et al. Adhesion protein VSIG1 is required for the proper differentiation of glandular gastric epithelia. PLoS One 6, e25908. https://doi.org/10.1371/journal.pone.0025908 (2011).
13. Chen, Y. et al. Decreased expression of V-set and immunoglobulin domain containing 1 (VSIG1) is associated with poor prognosis in primary gastric cancer. J. Surg. Oncol. 106, 286–293. https://doi.org/10.1002/jso.22150 (2012).
14. Nageotte, I. D. et al. WHO classification of tumours of the digestive system. Histopathology 2020(76), 182–188. https://doi.org/10.1111/his.13975 (2019).
15. Gurzu, S. et al. Proposal of a Dukes-MAC-like staging system for gastric cancer. J. Investig. Med. 65, 316–322. https://doi.org/10.1136/jim-2016-000270 (2017).
16. Lugli, A. et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Mod. Pathol. 30, 1299–1311. https://doi.org/10.1038/modpathol.2017.46 (2017).
17. Kano, K. et al. Association between lymph node ratio and survival in patients with pathological stage II/III gastric cancer. Ann. Surg. Oncol. 27, 4235–4247. https://doi.org/10.1089/ins.2019.11228 (2020).
18. Gurzu, S. et al. Interaction between cadherins, vimentin, and V-set and immunoglobulin domain containing 1 in gastric-type hepatocellular carcinoma. Histochim. Cell Biol. 156, 377–390. https://doi.org/10.1007/s10141-021-0206-8 (2021).
19. Banias, L. et al. Immunohistochemical-based molecular subtyping of colorectal cancer using maspin and markers of epithelial–mesenchymal transition. Oncol. Lett. 19, 1487–1495. https://doi.org/10.3892/ol.2019.11228 (2020).
20. VSIG1—V-set and immunoglobulin domain containing protein 1 precursor-Homo sapiens (Human)—VSIG1 gene and protein. https://www.uniprot.org/uniprot/Q86KX7. Accessed January 2, 2022.
21. VSIG1 protein expression summary—The Human Protein Atlas. https://www.proteinatlas.org/ENSG00000101842-VSIG1. Accessed January 2, 2022.
22. Kim, T. H. & Shvidrasani, R. A. Stomach development, stem cells and disease. Development 143, 554–565. https://doi.org/10.1242/dev.124891 (2016).
23. Kung, J. W., Currie, I. S., Forbes, S. J. & Ross, J. A. Liver development, regeneration, and carcinogenesis. J. Biomed. Biotechnol. 2010, 984248. https://doi.org/10.1155/2010/984248 (2010).
24. Barbacci, F. et al. Variant hepatocyte nuclear factor 1 is required for visceral endoderm specification. Development 126, 4795–4805 (1999).
25. Que, J., Luo, X., Schwartz, R. J. & Hogan, B. L. Multiple roles for Sox2 in the developing and adult mouse trachea. Development 136, 1899–1907. https://doi.org/10.1242/dev.034629 (2009).
26. Vega-Gomez, A., Shawlot, W., Sasaki, H., Behringer, R. R. & Ang, S. HNF3beta and Lim1 interact in the visceral endoderm to regulate primitive streak formation and anterior-posterior polarity in the mouse embryo. Development 126, 4499–4511 (1999).
27. Czubak-Prowizor, K., Babinska, A. & Swiatkowska, M. The F11 receptor (F11R)/junctional adhesion molecule-A (JAM-A) (F11R/JAM-A) in cancer progression. Mol. Cell. Biochem. 477, 79–98. https://doi.org/10.1007/s10497-021-04259-2 (2022).
28. Aban, C. E. et al. Downregulation of E-cadherin in pluripotent stem cells triggers partial EMT. Sci. Rep. 11, 2048. https://doi.org/10.1038/s41598-021-81735-1 (2021).
29. Li, L. E., Wei, Z. J., Sun, H. & Jiang, B. Abnormal β-catenin immunohistochemical expression as a prognostic factor in gastric cancer: A meta-analysis. World J. Gastroenterol. 20, 12313–12321. https://doi.org/10.3748/wjg.v20.i34.12313 (2014).
30. Gurzu, S., Kobori, L., Fodor, D. & Jung, I. Epithelial mesenchymal and endothelial mesenchymal transitions in hepatocellular carcinoma: A review. Biomed Res. Int. 2019, 2962580. https://doi.org/10.1155/2019/2962580 (2019).
31. Clevers, H. & Nusse, R. Wnt-β-catenin signaling and disease. Cell 149, 1192–1205. https://doi.org/10.1016/j.cell.2012.01.012 (2012).
32. Doupnas, N. et al. TCF/LEF dependent and independent transcriptional regulation of Wnt/β-catenin target genes. EMBO J. 38, e98873. https://doi.org/10.15252/embj.201798873 (2019).
33. Gurzu, S. et al. Non-Epstein–Barr virus associated lymphoepithelioma-like carcinoma of the esophagogastric junction with microsatellite instability K-ras wild type. *Pathol. Res. Pract.* **209**, 128–131. https://doi.org/10.1016/j.prp.2012.11.004 (2013).

**Acknowledgements**

The authors thanks to Ms. Genoveva Rigmanyi for tissue-microarray blocks sectioning and immunohistochemical staining, at the Research Center for Oncopathology and Translational Medicine (CCOMT). Cambridge Proofreading and Editing LLC team performed the professional English proofreading.

**Author contributions**

S.C.B. drafted the article, establish the study design, and contributed to the histopathological diagnosis; J.I. contributed to the diagnosis and immunohistochemical assessment; K.Z. and P.A.I. contributed to selection of patients, database design and R.I.S.-V.S. conferred the funding approval and supervised the scientific grant development; B.T. and M.C. performed the surgical interventions; G.S. supervised the study design, histopathological diagnosis and immunohistochemical assessment, and conferred the final agreement for publication.

**Funding**

This work was supported by the Romanian National Authority for Scientific Research, Project no. PCCF 20/2018.

**Competing interests**

The authors declare no competing interests.

**Additional information**

Correspondence and requests for materials should be addressed to S.G.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022